9:55 AM · 10 October 2024

GlaxoSmithKline surges 5% on Zantac settlement deal in the US

GSK plc
Stocks
GSK.US, GSK plc - ADR
-
-

Shares of British pharmaceutical giant, GlaxoSmithKline (GSK.US) more than 5% today amid $2.2 billion settlement deal in US Zantac lawsuits, caused by 'cancer-casuing' concerns. The deal will resolve 93% (almost 80,000) of US lawsuits. The company will recognize this loss in Q3 results, this year. All the settlements are expected to be implemented by the end of the first half of 2025. GSK confirmed also another $70 million paid to resolve the Zantac so-called qui tam complaint previously filed by Valisure. This agreement is pending final approval from the Department of Justice. Investors positively react to this news, improving 'uncertainty' about Zantac case.

 

Source: xStation5

 
 

 

7 October 2025, 10:25 AM

DE40: Europan market still under pressure of weak industry and political turmoil

6 October 2025, 7:14 PM

Daily summary: US100 surges almost 1% 📈Crypto and precious metals on the rise

6 October 2025, 3:06 PM

Stock of the Month: Will Meta win the AI ​​race?

6 October 2025, 1:03 PM

AMD rises on the wave of the OpenAI deal. Pre-market trading shows a 25% increase in shares.

Join over 1 700 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits